All In Biotech

Drug Trial Radar · NCT07806058

An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

An Open-Label, Multicenter, Phase IB/II Clinical Study of the Safety, Tolerability, and Efficacy of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IB/II clinical trial designed to evaluate HRS-7172 in combination with antitumor drugs in participants with advanced pancreatic cancer harboring RAS mutations or amplifications. The study process includes a screening period (from signed informed consent to first dose), a treatment period (from first dose to last dose), and a follow-up period (safety and survival follow-up after last dose). A Safety Monitoring Committee (SMC), composed of the principal investigator and sponsor representatives, will be established during the study to review the safety and efficacy data generated. The SMC will make decisions on study-related matters, including but not limited to combination regimen dose exploration, combination regimen selection, efficacy expansion cohort selection, expansion initiation timing, and recommended dose for expansion (RDE). This study aims to evaluate the safety, tolerability, and efficacy of HRS-7172 in combination with other antitumor therapies in participants with advanced or metastatic pancreatic cancer harboring RAS mutations or amplifications.

Conditions

  • Pancreatic Cancer

Interventions

  • HRS-7172 + AG + SHR-1316Drug

    HRS-7172 + AG + SHR-1316; low dose

  • HRS-7172 + AG + SHR-1316;Drug

    HRS-7172 + AG + SHR-1316; high dose

  • HRS-7172 + AG;Drug

    HRS-7172 + AG; low/high dose

  • HRS-7172 + AG + SHR-1316;Drug

    HRS-7172 + AG + SHR-1316; low/high dose

  • HRS-717 + HRS-4642+SHR-1316;Drug

    HRS-717 + HRS-4642+SHR-1316; low dose

  • HRS-717 + HRS-4642+SHR-1316;Drug

    HRS-717 + HRS-4642+SHR-1316; high dose

  • HRS-717 + HRS-4642;Drug

    HRS-717 + HRS-4642; low/high dose

  • HRS-717 + HRS-4642+SHR-1316;Drug

    HRS-717 + HRS-4642+SHR-1316; low/high dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RDE in advanced pancreatic cancer with RAS mutation or amplificationTime frame: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years
  2. Incidence and severity of adverse events (AEs) (per NCI-CTCAE V6.0 criteria)Time frame: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years
  3. ORR assessed by the investigatorTime frame: From the signing of the informed consent form to the end of the safety follow-up. Estimated to be 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.